Fertility Preservation
Buy print or eBook
[Opens in a new window] Principles and Practice
Book contents
- Fertility Preservation
- Fertility Preservation
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Foreword
- Preface
- Section 1 Introduction
- Section 2 Reproductive Biology and Cryobiology
- Section 3 Fertility Preservation in Cancer and Non-Cancer Patients
- Section 4 Fertility Preservation Strategies in the Male
- Section 5 Fertility Preservation Strategies in the Female: Medical/Surgical
- Section 6 Fertility Preservation Strategies in the Female: ART
- Section 7 Ovarian Cryopreservation and Transplantation
- Section 8 In Vitro Follicle Culture
- Section 9 New Research and Technologies
- Section 10 Ethical, Legal, and Religious Issues
- Index
- References
Section 5 - Fertility Preservation Strategies in the Female: Medical/Surgical
Published online by Cambridge University Press: 27 March 2021
Book contents
- Fertility Preservation
- Fertility Preservation
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Foreword
- Preface
- Section 1 Introduction
- Section 2 Reproductive Biology and Cryobiology
- Section 3 Fertility Preservation in Cancer and Non-Cancer Patients
- Section 4 Fertility Preservation Strategies in the Male
- Section 5 Fertility Preservation Strategies in the Female: Medical/Surgical
- Section 6 Fertility Preservation Strategies in the Female: ART
- Section 7 Ovarian Cryopreservation and Transplantation
- Section 8 In Vitro Follicle Culture
- Section 9 New Research and Technologies
- Section 10 Ethical, Legal, and Religious Issues
- Index
- References
- Type
- Chapter
- Information
- Fertility PreservationPrinciples and Practice, pp. 171 - 210Publisher: Cambridge University PressPrint publication year: 2021
References
References
Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2018. CA Cancer J Clin, 2018;68(1):7–30.CrossRefGoogle ScholarPubMed
Miller, KD, Siegel, RL, Lin, CC et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin, 2016;66(4):271–289.Google Scholar
Lambertini, M, Del Mastro, L, Pescio, MC et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med, 2016;14:1.CrossRefGoogle ScholarPubMed
ISFP Practice Committee, Kim, SS, Donnez, J et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet, 2012;29(6):465–468.Google Scholar
Peccatori, FA, Azim, HA Jr., Orecchia, R et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2013;24 Suppl 6:vi160–170.CrossRefGoogle ScholarPubMed
Paluch-Shimon, S, Pagani, O, Partridge, AH et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast, 2017;35:203–217.Google Scholar
Martinez, F. International Society for Fertility Preservation–ESHRE–ASRM Expert Working Group. Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives. Fertil Steril, 2017;108(3):407–415.e11.CrossRefGoogle Scholar
Oktay, K, Harvey, BE, Partridge, AH et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol, 2018;36(19):1994–2001.CrossRefGoogle ScholarPubMed
De Vos, M, Smitz, J, Woodruff, TK. Fertility preservation in women with cancer. Lancet, 2014;384(9950):1302–1310.Google Scholar
Turner, NH, Partridge, A, Sanna, G, Di Leo, A, Biganzoli, L. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol, 2013;24(9):2224–2235.Google Scholar
Blumenfeld, Z, Katz, G, Evron, A. “An ounce of prevention is worth a pound of cure”: the case for and against GnRH-agonist for fertility preservation. Ann Oncol, 2014;25(9):1719–1728.Google Scholar
Rodriguez-Wallberg, K, Turan, V, Munster, P, Oktay, K. Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients? Ann Oncol, 2016;27(2):257.Google Scholar
Del Mastro, L, Lambertini, M. Gonadotropin-releasing hormone analogs for ovarian function protection during chemotherapy in young early breast cancer patients: the last piece of the puzzle? Ann Oncol, 2017;28(8):1683–1685.Google Scholar
Lambertini, M, Cinquini, M, Moschetti, I et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer, 2017;71:25–33.Google Scholar
Chapman, RM, Sutcliffe, SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin’s disease. Blood, 1981;58(4):849–851.CrossRefGoogle ScholarPubMed
Kishk, EAF, Mohammed Ali, MH. Effect of a gonadotropin-releasing hormone analogue on cyclophosphamide-induced ovarian toxicity in adult mice. Arch Gynecol Obstet, 2013;287(5):1023–1029.Google Scholar
Tan, S-J, Yeh, Y-C, Shang, W-J et al. Protective effect of a gonadotropin-releasing hormone analogue on chemotherapeutic agent-induced ovarian gonadotoxicity: a mouse model. Eur J Obstet Gynecol Reprod Biol, 2010;149(2):182–185.Google Scholar
Demeestere, I, Streiff, AK, Suzuki, J et al. Follicle-stimulating hormone accelerates mouse oocyte development in vivo. Biol Reprod, 2012;87(1):3,1–11.Google Scholar
Rossi, V, Lispi, M, Longobardi, S et al. LH prevents cisplatin-induced apoptosis in oocytes and preserves female fertility in mouse. Cell Death Differ, 2017;24(1):72–82.Google Scholar
Blumenfeld, Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. The Oncologist, 2007;12(9):1044–1054.Google Scholar
Durlinger, AL, Kramer, P, Karels, B et al. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology, 1999;140(12):5789–5796.Google Scholar
Sánchez, F, Smitz, J. Molecular control of oogenesis. Biochim Biophys Acta, 2012;1822(12):1896–1912.Google Scholar
Roness, H, Gavish, Z, Cohen, Y, Meirow, D. Ovarian follicle burnout: a universal phenomenon? Cell Cycle, 2013;12(20):3245–3246.CrossRefGoogle ScholarPubMed
Hasky, N, Uri-Belapolsky, S, Goldberg, K et al. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma? Hum Reprod, 2015;30(5):1089–1101.Google Scholar
Kitajima, Y, Endo, T, Nagasawa, K et al. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology, 2006;147(2):694–699.CrossRefGoogle Scholar
Jayaprakasan, K, Campbell, BK, Hopkisson, JF et al. Effect of pituitary desensitization on the early growing follicular cohort estimated using anti-Mullerian hormone. Hum Reprod, 2008;23(11):2577–2583.Google Scholar
Dada, T, Salha, O, Allgar, V, Sharma, V. Utero-ovarian blood flow characteristics of pituitary desensitization. Hum Reprod, 2001;16(8):1663–1670.Google Scholar
Yu Ng, EH, Chi Wai, Chan C, Tang, OS, Shu Biu, Yeung W, Chung, Ho P. Effect of pituitary downregulation on antral follicle count, ovarian volume and stromal blood flow measured by three-dimensional ultrasound with power Doppler prior to ovarian stimulation. Hum Reprod, 2004;19(12):2811–2815.Google Scholar
Ben-Aharon, I, Granot, T, Meizner, I et al. Long-term follow-up of chemotherapy-induced ovarian failure in young breast cancer patients: the role of vascular toxicity. The Oncologist, 2015;20(9):985–991.Google Scholar
Meirow, D, Dor, J, Kaufman, B et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod Oxf Engl, 2007 June;22(6):1626–1633.Google Scholar
Codacci-Pisanelli, G, Del Pup, L, Del Grande, M, Peccatori, FA. Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients. Crit Rev Oncol Hematol, 2017;113:90–96.Google Scholar
Asimakopoulos, B, Nikolettos, N, Nehls, B et al. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertil Steril, 2006;86(3):636–641.Google Scholar
Harrison, GS, Wierman, ME, Nett, TM, Glode, LM. Gonadotropin-releasing hormone and its receptor in normal and malignant cells. Endocr Relat Cancer, 2004;11(4):725–748.CrossRefGoogle ScholarPubMed
Whitelaw, PF, Eidne, KA, Sellar, R, Smyth, CD, Hillier, SG. Gonadotropin-releasing hormone receptor messenger ribonucleic acid expression in rat ovary. Endocrinology, 1995;136(1):172–179.Google Scholar
Gründker, C, Emons, G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol, 2003;1:65.Google Scholar
Blumenfeld, Z, von Wolff, M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update, 2008;14(6):543–552.CrossRefGoogle ScholarPubMed
Sobinoff, AP, Nixon, B, Roman, SD, McLaughlin, EA. Staying alive: PI3 K pathway promotes primordial follicle activation and survival in response to 3MC-induced ovotoxicity. Toxicol Sci, 2012;128(1):258–271.Google Scholar
Kalich-Philosoph, L, Roness, H, Carmely, A et al. Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility. Sci Transl Med, 2013;5(185):185ra62.Google Scholar
Edwards, BS, Isom, WJ, Navratil, AM. Gonadotropin releasing hormone activation of the mTORC2/Rictor complex regulates actin remodeling and ERK activity in LβT2 cells. Mol Cell Endocrinol, 2017;439:346–353.Google Scholar
Ataya, KM, McKanna, JA, Weintraub, AM, Clark, MR, LeMaire, WJ. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res, 1985;45(8):3651–3656.Google Scholar
Bokser, L, Szende, B, Schally, AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer, 1990;61(6):861–865.Google Scholar
Ataya, K, Ramahi-Ataya, A. Reproductive performance of female rats treated with cyclophosphamide and/or LHRH agonist. Reprod Toxicol, 1993;7(3):229–235.CrossRefGoogle ScholarPubMed
Montz, FJ, Wolff, AJ, Gambone, JC. Gonadal protection and fecundity rates in cyclophosphamide-treated rats. Cancer Res, 1991;51(8):2124–2126.Google Scholar
Ataya, K, Rao, LV, Lawrence, E, Kimmel, R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod, 1995;52(2):365–372.CrossRefGoogle ScholarPubMed
Imai, A, Sugiyama, M, Furui, T, Tamaya, T, Ohno, T. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest, 2007;63(2):102–106.CrossRefGoogle ScholarPubMed
Bildik, G, Akin, N, Senbabaoglu, F et al. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro. Hum Reprod, 2015;30(12):2912–2925.Google Scholar
Yüce, MA, Balkanli Kaplan, P, Gücer, F et al. Prevention of cyclophosphamide-induced ovarian damage by concomitant administration of GnRHa in mice: a dose-dependent relationship? Eur J Gynaecol Oncol, 2004;25(5):628–631.Google ScholarPubMed
Horicks, F, Van Den Steen, G, Houben, S, Englert, Y, Demeestere, I. Folliculogenesis is not fully inhibited during GnRH analogues treatment in mice challenging their efficiency to preserve the ovarian reserve during chemotherapy in this model. PloS One, 2015;10(9):e0137164.Google Scholar
Li, M, Huang, H, Liang, Y, Tan, J, Lin, D. Effect of zoladex administered before chemotherapy on menstruation of patients with breast cancer. Chinese J Clin Oncol, 2008;35:905–907.Google Scholar
Badawy, A, Elnashar, A, El-Ashry, M, Shahat, M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril, 2009;91(3):694–697.Google Scholar
Sverrisdottir, A, Nystedt, M, Johansson, H, Fornander, T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat, 2009;117(3):561–567.Google Scholar
Gerber, B, von Minckwitz, G, Stehle, H et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol, 2011;29(17):2334–2341.Google Scholar
Sun, J, Ren, Y, Li, W. Effect of zoladex administered before chemotherapy on menstruation of patients with breast cancer. China Dis Med, 2011;19:15–16.Google Scholar
Del Mastro, L, Boni, L, Michelotti, A et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA, 2011;306(3):269–276.Google Scholar
Munster, PN, Moore, AP, Ismail-Khan, R et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol, 2012;30(5):533–538.Google Scholar
Elgindy, EA, El-Haieg, DO, Khorshid, OM et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol, 2013;121(1):78–86.Google Scholar
Song, G, Gao, H, Yuan, Z. Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol, 2013;30(3):667.Google Scholar
Jiang, FY, Zhang, QQ, Zeng, J. Protective effect of GnRHa on chemo-therapy induced ovarian damage in breast cancer patients. Shandong Med J, 2013;53(8):16–18.Google Scholar
Karimi-Zarchi, M, Forat-Yazdi, M, Vafaeenasab, MR et al. Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide. Eur J Gynaecol Oncol, 2014;35(1):59–61.Google Scholar
Moore, HCF, Unger, JM, Phillips, K-A et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med, 2015;372(10):923–932.Google Scholar
Lambertini, M, Boni, L, Michelotti, A et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA, 2015;314(24):2632–2640.Google Scholar
Leonard, RCF, Adamson, DJA, Bertelli, G et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol, 2017;28(8):1811–1816.Google Scholar
Zhang, Y, Ji, Y, Li, J et al. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival. Breast Cancer Res Treat, 2018;168(3):679–686.Google Scholar
Waxman, JH, Ahmed, R, Smith, D et al. Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol, 1987;19(2):159–162.Google Scholar
Giuseppe, L, Attilio, G, Edoardo, DN et al. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematol, 2007;12(2):141–147.Google Scholar
Behringer, K, Wildt, L, Mueller, H et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol, 2010;21(10):2052–2060.Google Scholar
Demeestere, I, Brice, P, Peccatori, FA et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol, 2013;31(7):903–909.Google Scholar
Demeestere, I, Brice, P, Peccatori, FA et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol, 2016;34(22):2568–2574.Google Scholar
Gilani, MM, Hasanzadeh, M, Ghaemmaghami, F, Ramazanzadeh, F. Ovarian preservation with gonadotropin-releasing hormone analog during chemotherapy. Asia Pac J Clin Oncol, 2007;3(2):79–83.Google Scholar
Clowse, MEB, Behera, MA, Anders, CK et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health 2002, 2009;18(3):311–319.Google Scholar
Ben-Aharon, I, Gafter-Gvili, A, Leibovici, L, Stemmer, SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat, 2010;122(3):803–811.Google Scholar
Kim, SS, Lee, JR, Jee, BC et al. Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol. 2010;53(4):740–752.Google Scholar
Bedaiwy, MA, Abou-Setta, AM, Desai, N et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril, 2011;95(3):906–914.e1-4.Google Scholar
Chen, H, Li, J, Cui, T, Hu, L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev, 2011;(11):CD008018.Google Scholar
Yang, B, Shi, W, Yang, J et al. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials. Breast, 2013;22(2):150–157.Google Scholar
Wang, C, Chen, M, Fu, F, Huang, M. Gonadotropin-releasing hormone analog cotreatment for the preservation of ovarian function during gonadotoxic chemotherapy for breast cancer: a meta-analysis. PloS One, 2013;8(6):e66360.Google Scholar
Zhang, Y, Xiao, Z, Wang, Y et al. Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients. PloS One, 2013;8(11):e80444.Google Scholar
Sun, X, Dongol, S, Jiang, J, Kong, B. Protection of ovarian function by GnRH agonists during chemotherapy: a meta-analysis. Int J Oncol, 2014;44(4):1335–1340.Google Scholar
Del Mastro, L, Ceppi, M, Poggio, F et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev, 2014;40(5):675–683.CrossRefGoogle ScholarPubMed
Vitek, WS, Shayne, M, Hoeger, K et al. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. Fertil Steril, 2014;102(3):808–815.e1.Google Scholar
Elgindy, E, Sibai, H, Abdelghani, A, Mostafa, M. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis. Obstet Gynecol, 2015;126(1):187–195.Google Scholar
Shen, Y-W, Zhang, X-M, Lv, M et al. Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis. OncoTargets Ther, 2015;8:3349–3359.CrossRefGoogle ScholarPubMed
Lambertini, M, Ceppi, M, Poggio, F et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol, 2015;26(12):2408–2419.Google Scholar
Munhoz, RR, Pereira, AAL, Sasse, AD et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol, 2016;2(1):65–73.Google Scholar
Silva, C, Caramelo, O, Almeida-Santos, T, Ribeiro Rama, AC. Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis. Hum Reprod, 2016;31(12):2737–2749.Google Scholar
Bai, F, Lu, Y, Wu, K et al. Protecting effects of gonadotropin-releasing hormone agonist on chemotherapy-induced ovarian damage in premenopausal breast cancer patients: a systematic review and meta-analysis. Breast Care, 2017;12(1):48–52.CrossRefGoogle ScholarPubMed
Senra, JC, Roque, M, Talim, MCT, Reis, FM, Tavares, RLC. Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis. Ultrasound Obstet Gynecol, 2018;51(1):77–86.Google Scholar
Hickman, LC, Llarena, NC, Valentine, LN, Liu, X, Falcone, T. Preservation of gonadal function in women undergoing chemotherapy: a systematic review and meta-analysis of the potential role for gonadotropin-releasing hormone agonists. J Assist Reprod Genet, 2018;35(4):571–581.Google Scholar
Lambertini, M, Moore, HCF, Leonard, RCF et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol, 2018;36(19):1981–1990.Google Scholar
Lambertini, M, Goldrat, O, Clatot, F, Demeestere, I, Awada, A. Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art. Curr Opin Oncol, 2017;29(4):243–252.Google Scholar
European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber, L, Davies, M et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod, 2016;31(5):926–937.Google Scholar
Meirow, D, Rabinovici, J, Katz, D et al. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer, 2006;107(7):1634–1641.Google Scholar
References
Lawrenz, B, Jauckus, J, Kupka, MS et al. Fertility preservation in >1,000 patients: patient’s characteristics, spectrum, efficacy and risks of applied preservation techniques. Arch Gynecol Obstet, 2011;283:651–656.Google Scholar
Jennings, E, Hilders, CG, Louwe, LA, Peters, AA. Female fertility preservation: practical and ethical considerations of an underused procedure. Cancer J, 2008;14:333–339.Google Scholar
Tulandi, T, Huang, JY, Tan, SL. Preservation of female fertility: an essential progress. Obstet Gynecol, 2008;112:1160–1172.Google Scholar
Georgeseu, E, Goldberg, J, du Plessis, S, Agarwal, A. Present and future fertility preservation strategies for female cancer patients. Obstet Gynecol Surv, 2008;63:725–733.Google Scholar
Falcone, T, Bedaiwy, M. Fertility preservation and pregnancy outcome after malignancy. Curr Opin Obstet Gynecol, 2005;17:21–26.Google Scholar
Azem, F, Yovel, I, Wagman, I et al. Surrogate pregnancy in a patient who underwent radical hysterectomy and bilateral transposition of ovaries. Fertil Steril, 2003;79:1229–1130.Google Scholar
Hadar, H, Loven, D, Herskovitz, P et al. An evaluation of lateral and medial transposition of the ovaries out of radiation fields. Cancer, 1994;74:774–779.Google Scholar
Wallace, WHB, Shalet, SM, Hendy, JH et al. Ovarian failure following abdominal irradiation in childhood. The radiosensitivity of human oocyte. Br J Radiol, 1989;62:995–998.Google Scholar
Wallace, WH, Thomson, AB, Saran, F, Kelsey, TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys, 2005;62:738–744.Google Scholar
Wo, J, Viseanathan, A. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys, 2009;73:1304–1312.Google Scholar
Ghadjar, P, Budach, V, Köhler, C, Jantke, A, Marnitz, S. Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation. Radiation Oncol, 2015;10(50):353–354.Google Scholar
Chiarelli, AM, Marrett, LD, Darlington, G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964–1988 in Ontario, Canada. Am J Epidemiol, 1999;150:245–254.Google Scholar
Ray, GR, Trueblood, HW, Enright, LP et al. Oophoropexy: a means of preserving ovarian function following pelvic megavoltage radiotherapy for Hodgkin’s disease. Radiol, 1970;96:175–180.Google Scholar
Belinson, JL, Doherty, M, McDay, JB. A new technique for ovarian transposition. Surg Gynecol Obstet, 1984;159:157–160.Google Scholar
Covens, AL, van der Putten, HW, Fyles, AW et al. Laparoscopic ovarian transposition. Eur J Gynaecol Oncol, 1996;17:177–182.Google Scholar
Thibaud, E, Ramirez, M, Brauner, R et al. Preservation of ovarian function by ovarian transposition performed before pelvic irradiation during childhood. J Pediatr, 1992;121:880–884.Google Scholar
Bisharah, M, Tulandi, T. Laparoscopic preservation of ovarian function: an underused procedure. Am J Obstet Gynecol, 2003;188:367–370.Google Scholar
Morice, P, Juncker, L, Rey, A et al. Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination. Fertil Steril, 2000;74:743–748.Google Scholar
Morice, P, Thiam-Ba, R, Castaigne, D et al. Fertility results after ovarian transposition for pelvic malignancies treated by external irradiation or brachytherapy. Hum Reprod, 1998;13:660–663.Google Scholar
Williams, RS, Littell, RD, Mendenhall, NP. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease. Cancer, 1999 November 15;86:2138–2142.Google Scholar
Hwang, JH, Yoo, HJ, Park, SH et al. Association between the location of transposed ovary and ovarian function in patients with uterine cervical cancer treated with (postoperative or primary) pelvic radiotherapy. Fertil Steril, 2012;97:1387–1393.Google Scholar
Huang, KG, Lee, CL, Tsai, CS, Han, CM, Hwang, LL. A new approach for laparoscopic ovarian transposition before pelvic irradiation. Gynecol Oncol, 2007;105:234–237.CrossRefGoogle ScholarPubMed
Van Eijkeren, MA, Van DerWijk, I, Al Sharouni, SY et al. Benefits and side effects of lateral ovarian transposition (LOT) performed during radical hysterectomy and pelvic lymphadenectomy for early stage cervical cancer. Int J Gynecol Cancer, 1999;9:396–400.Google Scholar
Feeney, DD, Moore, DH, Look, KY, Stehman, FB, Sutton, GP. The fate of the ovaries after radical hysterectomy and ovarian transposition. Gynecol Oncol, 1995;56:3–7.Google Scholar
Kuohung, W, Ram, K, Cheng, DM et al. Laparoscopic oophoropexy prior to radiation for pediatric brain tumor and subsequent ovarian function. Hum Reprod, 2008;23:117–121.Google Scholar
Pahisa, J, Martínez-Román, S, Martínez-Zamora, MA et al. Laparoscopic ovarian transposition in patients with early cervical cancer. Int J Gynecol Cancer, 2008;18:584–589.Google Scholar
Terenziani, M, Piva, L, Meazza, C et al.Oophoropexy: a relevant role in preservation of ovarian function after pelvic irradiation. Fertil Steril, 2009;91:935.e15–6.Google Scholar
Iavazzo, C, Filippos, M, Gkegkes, I. The role of robotics in ovarian transposition. Acta Inform Med, 2013;21:135–137.Google Scholar
Al-Badawi, I, Al-Aker, M, Tulandi, T. Robotic-assisted ovarian transposition before radiation. Surg Technol Int, 2010;19:141–143.Google Scholar
Gubbala, K, Laios, A, Gallos, I et al. Outcomes of ovarian transposition in gynaecological cancers; a systematic review and meta-analysis. J Ovarian Research, 2014;7:69.Google Scholar
Gómez-Hidalgo, NR, Darin, MC, Dalton, H et al. Ovarian torsion after laparoscopic ovarian transposition in patients with gynecologic cancer: a report of two cases. J Minim Invasive Gynecol, 2015;22:687–690.Google Scholar
References
Ferlay, J, Soerjomataram, I, Dikshit, R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015;136(5):E359–E386.Google Scholar
Howlader, N, Noone, AM, Krapcho, M et al. (eds.). SEER Cancer Statistics Review, 1975–2012. Bethesda, MD: National Cancer Institute, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.Google Scholar
Bentivegna, E, Gouy, S, Maulard, A et al. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncol, 2016;17:e240–e253.Google Scholar
Wright, JD, NathavithArana, R, Lewin, SN et al. Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access. Obstet Gynecol, 2010;115:585–590.Google Scholar
Hartman, CA, Teixeira, JC, Barbosa, SB et al. Analysis of conservative surgical treatment and prognosis of microinvasive squamous cell carcinoma of the cervix stage IA1: results of follow-up to 20 years. Int J Gynecol Cancer, 2017 February;27(2):357–363.Google Scholar
Spoozak, L, Lewin, SN, Burke, WM et al. Microinvasive adenocarcinoma of the cervix. Am J Obstet Gynecol, 2012;206:80:e1–6.Google Scholar
Cibula, D, Pötter, R, Planchamp, F et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiother Oncol, 2018 June;127(3):404–416.Google Scholar
Winter, WE 3rd, Kucera, PR, Rodgers, W et al. Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol, 2002;100:671–676.Google Scholar
Colombo, N, Carinelli, S, Colombo, A et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012;23(Suppl 7):vii27–32.Google Scholar
Baiocchi, G, de Brot, L, Faloppa, CC et al. Is parametrectomy always necessary in early-stage cervical cancer? Gynecol Oncol, 2017;146(1): 16–19.Google Scholar
Shim, SH, Lim, MC, Kim, HJ et al. Can simple trachelectomy or conization show comparable survival rate compared with radical trachelectomy in IA1 cervical cancer patients with lymphovascular space invasion who wish to save fertility? A systematic review and guideline recommendation. PLoS One, 2018 January 31;13(1):e0189847.Google Scholar
Gien, LT, Covens, A. Fertility-sparing options for early stage cervical cancer. Gynecol Oncol, 2010;117:350–357.Google Scholar
Dargent, D, Martin, X, Sacchetoni, A, Mathevet, P. Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients. Cancer, 2000;88:1877–1882.Google Scholar
Xu, L, Sun, FQ, Wang, ZH. Radical trachelectomy versus radical hysterectomy for the treatment of early cervical cancer: a systematic review. Acta Obstet Gynecol Scand, 2011;90:1200–1209.Google Scholar
Zapardiel, I, Cruz, M, Diestro, MD, Requena, A, Garcia-Velasco, JA. Assisted reproductive techniques after fertility-sparing treatments in gynaecological cancers. Hum Reprod Update, 2016; 22(3):28–305.Google Scholar
Machida, H, Mandelbaum, RS, Mikami, M et al. Characteristics and outcomes of reproductive-aged women with early-stage cervical cancer: trachelectomy versus hysterectomy. Am J Obstet Gynecol, 2018 August 20. pii: S0002–9378(18):30673–30672.Google Scholar
Helpman, L, Grisaru, D, Covens, A. Early adenocarcinoma of the cervix: is radical vaginal trachelectomy safe? Gynecol Oncol, 2011;123:95–98.Google Scholar
Plante, M, Gregoire, J, Renaud, MC, Roy, M. The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies. Gynecol Oncol, 2011;121: 290–297.Google Scholar
Hoogendam, JP, Zweemer, RP, Hobbelink, MG et al. 99mTc-Nanocolloid SPECT/MRI fusion for the selective assessment of nonenlarged sentinel lymph nodes in patients with early-stage cervical cancer. J Nucl Med, 2016 April;57(4):551–556.Google Scholar
Lakhman, Y1, Akin, O, Park, KJ et al. Stage IB1 cervical cancer: role of preoperative MR imaging in selection of patients for fertility-sparing radical trachelectomy. Radiology, 2013 October;269(1):149–158.Google Scholar
Shepherd, JH, Spencer, C, Herod, J, Ind, TE. Radical vaginal trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer-cumulative pregnancy rate in a series of 123 women. BJOG, 2006;113:719–724.Google Scholar
Rob, L, Skapa, P, Robova, H. Fertility-sparing surgery in patients with cervical cancer. Lancet Oncol, 2011;12: 192–200.Google Scholar
Delgado, G, Bundy, B, Zaino, R et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol, 1990;38:352–357.Google Scholar
Plante, M, Lau, S, Brydon, L et al. Neoadjuvant chemotherapy followed by vaginal radical trachelectomy in bulky stage IB1 cervical cancer: case report. Gynecol Oncol, 2006;101:367–370.Google Scholar
Robova, H, Halaska, MJ, Pluta, M et al. Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer. Gynecol Oncol, 2014;135:213–216.Google Scholar
Saso, S, Ghaem-Maghami, S, Chatterjee, J et al. Abdominal radical trachelectomy in West London. BJOG, 2012;119:187–193.Google Scholar
Lintner, B, Saso, S, Tarnai, L et al. Use of abdominal radical trachelectomy to treat cervical cancer greater than 2 cm in diameter. Int J Gynecol Cancer, 2013;23:1065–1070.Google Scholar
Salihi, R, Leunen, K, Van Limbergen, E et al. Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer. Gynecol Oncol, 2015;139:447–451.Google Scholar
Saadi, JM, Perrotta, M, Orti, R et al. Laparoscopic radical trachelectomy: technique, feasibility, and outcomes. JSLS, 2015;19:e2013.00248.CrossRefGoogle ScholarPubMed
Pareja, R, Rendon, GJ, Vasquez, M et al. Immediate radical trachelectomy versus neoadjuvant chemotherapy followed by conservative surgery for patients with stage IB1 cervical cancer with tumors 2 cm or larger: A literature review and analysis of oncological and obstetrical outcomes. Gynecol Oncol, 2015;137:574–580.Google Scholar
Bentivegna, E, Maulard, A, Pautier, P et al. Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature. Fertil Steril, 2016 October;106(5):1195–1211.Google Scholar
Kasuga, Y, Nishio, H, Miyakoshi, K et al. Pregnancy outcomes after abdominal radical trachelectomy for early-stage cervical cancer: a 13-year experience in a single tertiary-care center. Int J Gynecol Cancer, 2016;26:163–168.Google Scholar
Li, X, Li, J, Wu, X. Incidence, risk factors and treatment of cervical stenosis after radical trachelectomy: a systematic review. Eur J Cancer, 2015;51:1751–1759.Google Scholar
Ghadjar, P, Budach, V, Kohler, C, Jantke, A, Marnitz, S. Modern radiation therapy and potential fertility preservation strategies in patients with cervical cancer undergoing chemoradiation. Radiat Oncol, 2015;10:50.Google Scholar
Donnez, J, Dolmans, MM. Fertility preservation in women. Nat Rev Endocrinol, 2013;9:735–749.Google Scholar
Pareja, R, Rendon, GJ, Sanz-Lomana, CM, Monzon, O, Ramirez, PT. Surgical, oncological, and obstetrical outcomes after abdominal radical trachelectomy – a systematic literature review. Gynecol Oncol, 2013;131:77–82.Google Scholar
Kasuga, Y, Miyakoshi, K, Nishio, H et al. Mid-trimester residual cervical length and the risk of preterm birth in pregnancies after abdominal radical trachelectomy: a retrospective analysis. BJOG, 2017 October;124(11):1729–1735.Google Scholar
Alvarez, RM, Biliatis, I, Rockall, A et al. MRI measurement of residual cervical length after radical trachelectomy for cervical cancer and the risk of adverse pregnancy outcomes: a blinded imaging analysis. BJOG. 2018 August 12. DOI:10.1111/1471-0528.15429. [Epub ahead of print].Google Scholar
Mathevet, P, Laszlo de, Kaszon E, Dargent, D. Fertility preservation in early cervical cancer. Gynecol Obstet Fertil, 2003;31:706–712.Google Scholar
Lintner, B, Saso, S, Tarnai, L et al. Use of abdominal radical trachelectomy to treat cervical cancer greater than 2 cm in diameter. Int J Gynecol Cancer, 2013;23:1065–1070.Google Scholar
Mangler, M, Lanowska, M, Bartens, A et al. Closure of the cervical os in patients after fertility preserving treatment for early cervical cancer – results of a prospective observational study. J Perinat Med, 2017 November 27;45(8):941–945.Google Scholar
Lee, TS, Jung, JY, Kim, JW et al. Feasibility of ovarian preservation in patients with early stage endometrial carcinoma. Gynecol Oncol, 2007;104:52–57.Google Scholar
Renehan, AG, Tyson, M, Egger, M, Heller, RF, Zwahlen, M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet, 2008;371:569–578.Google Scholar
Navarria, I, Usel, M, Rapiti, E et al. Young patients with endometrial cancer: how many could be eligible for fertility-sparing treatment? Gynecol Oncol, 2009;114:448–451.Google Scholar
Koh, WJ, Greer, BE, Abu-Rustum, NR et al. Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw, 2014;12:248–280.Google Scholar
Rodolakis, A, Biliatis, I, Morice, P et al. European Society of Gynecological Oncology Task Force for Fertility Preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients. Int J Gynecol Cancer, 2015;25:1258–1265.Google Scholar
Park, JY, Kim, DY, Kim, TJ et al. Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstet Gynecol, 2013 July;122(1):7–14.Google Scholar
Yuk, JS, Song, JY, Lee, JH et al. Levonorgestrel-releasing intrauterine systems versus oral cyclic medroxyprogesterone acetate in endometrial hyperplasia therapy: a meta-analysis. Ann Surg Oncol, 2017;24:1322–1329.Google Scholar
Gunderson, CC, Fader, AN, Carson, KA et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol, 2012;125:477–482.Google Scholar
Ushijima, K, Yahata, H, Yoshikawa, H et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol, 2007;25:2798–2803.Google Scholar
Park, JY, Lee, SH, Seong, SJ et al. Progestin retreatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol, 2013;129:7–11.Google Scholar
Greenwald, ZR, Huang, LN, Wissing, MD et al. Does hormonal therapy for fertility preservation affect the survival of young women with early stage endometrial cancer? Cancer, 2017;123:1545–1554.Google Scholar
Park, JY, Seong, SJ, Kim, TJ et al. Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer. Gynecol Oncol, 2017 July;146(1):39–43.Google Scholar
Alonso, S, Castellanos, T, Lapuente, F et al. Hysteroscopic surgery for conservative management in endometrial cancer: a review of the literature. Ecancermedicalscience, 2015;9:505.Google Scholar
Jadoul, P, Donnez, J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril, 2003 December;80(6):1315–1324.Google Scholar
Chiva, L, Lapuente, F, Gonzalez-Cortijo, L et al. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol, 2008;111(Suppl):S101–S104.Google Scholar
Gonthier, C, Walker, F, Luton, D et al. Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer. Gynecol Oncol, 2014;133:33–37.Google Scholar
Rodolakis, A, Biliatis, I, Morice, P et al. European Society of Gynecological Oncology Task Force for Fertility Preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients. Int J Gynecol Cancer, 2015;25:1258–1265.Google Scholar
Juretzka, MM, O’ Hanlan, KA, Katz, SL, El-Danasouri, I, Westphal, LM. Embryo cryopreservation after diagnosis of stage IIB endometrial cancer and subsequent pregnancy in a gestational carrier. Fertil Steril, 2005;83:1041.Google Scholar
Martınez, F, Devesa, M, Coroleu, B et al. Cancer and fertility preservation: Barcelona consensus meeting. Gynecol Endocrinol, 2013 April;29(4):285–291.Google Scholar
Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2016. CA Cancer J Clin, 2016;66:7–30.Google Scholar
Skirnisdottir, I, Garmo, H, Wilander, E, Holmberg, L. Borderline ovarian tumors in Sweden 1960–2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer, 2008;123:1897–1901.Google Scholar
Zanetta, G, Rota, S, Chiari, S et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol, 2001;19:2658–2664.Google Scholar
du Bois, A, Ewald-Riegler, N, de Gregorio, N et al.; Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) study group borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) study group. Eur J Cancer, 2013 May;49(8):1905–1914.Google Scholar
Morice, P, Camatte, S, El Hassan, J et al. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril, 2001 January;75(1):92–96.Google Scholar
Donnez, J, Munschke, A, Berliere, M et al. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertil Steril, 2003 May;79(5):1216–1221.Google Scholar
Zanetta, G, Rota, S, Lissoni, A et al. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol Oncol, 2001 April;81(1):63–66.Google Scholar
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol, 2007;110:201–214.Google Scholar
du Bois, A, Trillsch, F, Mahner, S, Heitz, F, Harter, P. Management of borderline ovarian tumors. Ann Oncol, 2016 April;27(Suppl 1):i20–i22.Google Scholar
Vasconcelos, I, de Sousa, Mendes M. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk. Eur J Cancer, 2015 March;51(5):620–631.Google Scholar
Fauvet, R, Boccara, J, Dufournet, C et al. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study. Cancer, 2004;100:1145–1151.Google Scholar
Suh-Burgmann, E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol, 2006;103:841–847.Google Scholar
Helpman, L, Beiner, ME, Aviel-Ronen, S et al. Safety of ovarian conservation and fertility preservation in advanced borderline ovarian tumors. Fertil Steril, 2015 July;104(1):138–44.Google Scholar
Uzan, C, Muller, E, Kane, A et al. Prognostic factors for recurrence after conservative treatment in a series of 119 patients with stage I serous borderline tumors of the ovary. Ann Oncol, 2014;25:166–171.Google Scholar
Vasconcelos, I, Darb-Esfahani, S, Sehouli, J. Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high-risk histopathological features, and lethal recurrence rates. BJOG, 2016;123:498–508.Google Scholar
Nam, JH. Borderline ovarian tumors and fertility. Curr Opin Obstet Gynecol, 2010 June;22(3):227–234.Google Scholar
Daraï, E, Fauvet, R, Uzan, C et al. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update, 2013 March–April;19(2):151–166.Google Scholar
Denschlag, D, von Wolff, M, Amant, F et al. Clinical recommendation on fertility preservation in borderline ovarian neoplasm: ovarian stimulation and oocyte retrieval after conservative surgery. Gynecol Obstet Invest, 2010;70(3):160–165.Google Scholar
Morice, P, Denschlag, D, Rodolakis, A et al.; Fertility Task Force of the European Society of Gynecologic Oncology.Recommendations of the fertility task force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. Int J Gynecol Cancer, 2011 July;21(5):951–963.Google Scholar
Redman, C, Duffy, S, Bromham, N, Francis, K. Guideline Development Recognition and initial management of ovarian cancer: summary of NICE guidance. BMJ, 2011;342:d2073.Google Scholar
Bentivegna, E, Fruscio, R, Roussin, S et al. Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients. Fertil Steril, 2015 November;104(5):1319–1324.Google Scholar
Ghezzi, F, Cromi, A, Fanfani, F et al. Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: A multi-institutional experience. Gynecol Oncol, 2016 June;141(3):461–465.Google Scholar
Zapardiel, I, Cruz, M, Diestro, MD, Requena, A, Garcia-Velasco, JA. Assisted reproductive techniques after fertility-sparing treatments in gynaecological cancers. Hum Reprod Update, 2016 April;22(3):281–305.Google Scholar
Smith, HO, Berwick, M, Verschraegen, CF et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol, 2006 May;107(5):1075–1085.Google Scholar
Park JY, Kim DY, Suh DS et al. Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors. Gynecol Oncol. 2017 Jun;145(3):513–518Google Scholar
Jorge, S, Jones, NL, Chen, L et al. Characteristics, treatment and outcomes of women with immature ovarian teratoma, 1998–2012. Gynecol Oncol, 2016 August;142(2):261–266.Google Scholar
Kang, H, Kim, TJ, Kim, WY et al. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol, 2008;111:106–110.Google Scholar
Mangili, G, Sigismondi, C, Lorusso, D et al. Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience. Gynecol Oncol, 2011;121:280–284.Google Scholar
Reed, N, Millan, D, Verheijen, R, Castiglione, M; ESMO Guidelines Working Group. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010 May;21(Suppl 5):v31-6.Google Scholar
Cushing, B, Giller, R, Cullen, JW et al.; Pediatric Oncology Group 9049; Children’s Cancer Group 8882. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study–Pediatric Oncology Group 9049 and Children’s Cancer Group 8882. J Clin Oncol, 2004 July 1;22(13):2691–2700.Google Scholar
Billmire, DF, Cullen, JW, Rescorla, FJ et al. Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children’s Oncology Group. J Clin Oncol, 2014;32:465–470.Google Scholar
References
Taylor, HC. Malignant and semi-malignant tumors of the ovary. Surg Gynecol Obstet, 1929;48:204–230.Google Scholar
Hart, WR, Norris, HJ. Borderline and malignant mucinous tumors of the ovary. Cancer, 1973;31:1031–1044.Google Scholar
Bell, DA, Weinstock, MA, Scully, RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer, 1988;62:2212–2222.Google Scholar
Duvillard, P. Tumeurs ovariennes à la limite de la malignité. Ann. Pathol, 1996;16:396–405.Google Scholar
Gershenson, D, Silva, E, Levy, L et al. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer, 1998;82:1096–1103.Google Scholar
Gershenson, D, Silva, EL, Tortolero-Luna, G et al. Serous borderline tumors of the ovary with non invasive peritoneal implants. Cancer, 1998;83:2157–2163.Google Scholar
Seidman, JD, Kurman, RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol, 1996;20:1331–1345.Google Scholar
Kane, A, Uzan, C, Rey, A, Gouy, S et al. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants. Oncologist, 2009;14:591–600.Google Scholar
Seidman, JD, Kurman, RJ. Treatment of micropapillary serous ovarian carcinoma (the aggressive variant of serous borderline tumors. Cancer, 2002;95:675–676.Google Scholar
Eichhorn, JH, Bell, DA, Young, RH et al. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol, 1999;23:397–409.Google Scholar
Morice, P, Uzan, C, Fauvet, R et al. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol, 2012 March;13(3):e103–e115.Google Scholar
Trimble, CL, Kosary, C, Trimble, EL. Long-term and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol, 2002;86:34–37.Google Scholar
Daraï, E, Fauvet, R, Uzan, C et al. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update, 2013 March–April;19(2):151–166.Google Scholar
Palomba, S, Zupi, E, Russo, T et al. Comparison of two fertility-sparing approaches for bilateral borderline ovarian tumours: a randomized controlled study. Hum Reprod, 2007;22:578–585.Google Scholar
Palomba, S, Falbo, A, Del Negro, S et al. Ultra-conservative fertility-sparing strategy for bilateral borderline ovarian tumours: an 11-year follow-up. Hum Reprod, 2010;25:1966–1972.Google Scholar
Bendifallah, S, Ballester, M, Uzan, C et al. Nomogram to predict recurrence in patients with early and advanced-stage mucinous and serous borderline ovarian tumors. Am J Obstet Gynecol, 2014 December;211(6):637.e1–6.Google Scholar
Morice, P, Uzan, C, Fauvet, R et al. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol, 2012 March;13(3):e103–e115.Google Scholar
Uzan, C, Nikpayam, M, Ribassin-Majed, L et al. Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments. Ann Oncol, 2014 July;25(7):1312–1319.Google Scholar
du Bois, A, Ewald-Riegler, N, de Gregorio, N et al.; Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer, 2013 May;49(8):1905–1914.Google Scholar
Fauvet, R, Poncelet, C, Boccara, J et al. Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertil Steril, 2005;83:284–290, quiz 525–286.Google Scholar
Kanat-Pektas, M, Ozat, M, Gungor, T et al. Fertility outcome after conservative surgery for borderline ovarian tumors: a single center experience. Arch Gynecol Obstet, 2011;284:1253–1258.Google Scholar
Trillsch, F, Mahner, S, Woelber, L et al. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. Ann Oncol, 2014 July;25(7):1320–1327.Google Scholar
Fauvet, R, Demblocque, E, Morice, P, Querleu, D, Darai, E. Behavior of serous borderline ovarian tumors with and without micropapillary patterns: results of a French multicenter study. Ann Surg Oncol, 2012;19:941–947.Google Scholar
Ouldamer, L, Bendifallah, S, Naoura, I et al. Nomogram to predict live birth rate after fertility-sparing surgery for borderline ovarian tumours. Hum Reprod, 2016 August;31(8):1732–1737.Google Scholar
Rizzuto, I1, Behrens, RF, Smith, LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev, 2013 August;13(8):CD008215.Google Scholar
Basille, C, Olivennes, F, Le Calvez, J et al. Impact of gonadotrophins and steroid hormones on tumour cells derived from borderline ovarian tumours. Hum Reprod, 2006;21:3241–3245.Google Scholar
Nijman, HW, Burger, CW, Baak, JP et al. Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases. Eur J Cancer, 1992;28A:1971–1972.Google Scholar
Mantzavinos, T, Kanakas, N, Genatas, C et al. Five years’ follow-up in two patients with borderline tumors of the ovary hyperstimulated by gonadotrophin therapy for in-vitro fertilization. Hum Reprod, 1994;9:2032–2033.Google Scholar
Lawal, AH, Lynch, CB. Borderline ovarian cancer, bilateral surgical castration, chemotherapy and a normal delivery after ovum donation and in vitro fertilisation-embryo transfer. Br J Obstet Gynaecol, 1996;103:931–932.Google Scholar
Hoffman, JS, Laird, L, Benadiva, C et al. In vitro fertilization following conservative management of stage 3 serous borderline tumor of the ovary. Gynecol Oncol, 1999;74:515–518.Google Scholar
Gallot, D, Pouly, JL, Janny, L et al. Successful transfer of frozen-thawed embryos obtained immediately before radical surgery for a stage IIIa serus borderline ovarian tumor: Case report. Hum Reprod, 2000;15:2347–2350.Google Scholar
Morris, RT, Gershenson, DM, Silva, EG et al. Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol, 2000;95:541–547.Google Scholar
Beiner, ME, Gotlieb, WH, Davidson, B et al. Infertility treatment after conservative management of borderline ovarian tumors. Cancer, 2001;92:320–325.Google Scholar
Attar, E, Berkman, S, Topuz, S et al. Evolutive peritoneal disease after conservative management and the use of infertility drugs in a patient with stage IIIC borderline micro-papillary serous carcinoma (MPSC) of the ovary: case report. Hum Reprod, 2004;19:1472–1475.Google Scholar
Fasouliotis, SJ, Davis, O, Schattman, G et al. Safety and efficacy of infertility treatment after conservative management of borderline ovarian tumors: a preliminary report. Fertil Steri, 2004;82:568–572.Google Scholar
Marcickiewicz, J, Brannstrom, M. Fertility preserving surgical treatment of borderline ovarian tumour: long-term consequence for fertility and recurrence. Acta Obtet Gynecol Scand, 2006;85:1496–1500.Google Scholar
Fortin, A, Morice, P, Thoury, A et al. Impact of infertility drugs after treatment of borderline ovarian tumors: results of a retrospective multicenter study. Fertil Steril, 2007;87:591–596.Google Scholar
Park, CW, Yang, KM, Kim, HO et al. Outcomes of controlled ovarian hyperstimulation/in vitro fertilization for infertile patients with borderline ovarian tumor after conservative treatment. J Korean Med Sci, 2007;22 Suppl:S134–S138.Google Scholar
Yinon, Y, Beiner, ME, Gotlieb, WH et al. Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors. Fertil Steril, 2007;88:479–484.CrossRefGoogle ScholarPubMed
Porcu, E, Venturoli, S, Damiano, G et al. Healthy twins delivered after oocyte cryopreservation and bilateral ovariectomy for ovarian cancer. Reprod Biomed Online, 2008;17:265–267.Google Scholar
Cabenda-Narain, NE, Jansen, FW, Dieben, SW, Verburg, HJ, Gaarenstroom, KN. Conservatively treated borderline ovarian tumours, followed by IVF treatment: a case series. J Obstet Gynaecol, 2011;31:327–329.Google Scholar
Koskas, M, Uzan, C, Gouy, S et al. Fertility determinants after conservative surgery for mucinous borderline tumours of the ovary (excluding peritoneal pseudomyxoma). Hum Reprod, 2011;26:808–814.Google Scholar
DiSaia, P.J. Conservative management of the patient with early gynecologic cancer. CA Cancer J Clin, 1989;39:135–154.Google Scholar
Colombo, N, Chiari, S, Maggioni, A et al. Controversial issues in the management of early epithelial ovarian cancer: conservative surgery and role of adjuvant therapy. Gynecol Oncol, 1994;55:S47–S51.Google Scholar
Zanetta, G, Chiari, S, Rota, S et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol, 1997;104:1030–1035.Google Scholar
Schilder, JM, Thompson, AM, DePriest, PD et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol, 2002;87:1–7.Google Scholar
Morice, P, Leblanc, E, Rey, A et al. GCCLCC and SFOG. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d’Oncologie Gynécologique). Hum Reprod, 2005;20:1379–1385.Google Scholar
Park, JY, Kim, DY, Suh, DS et al. Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol, 2008;110:345–353.Google Scholar
Satoh, T, Hatae, M, Watanabe, Y et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. [Erratum appears in J Clin Oncol 2011 Dec 10;29(35):4725] J of Clini Oncol, 2010;28(10):1727–1732.Google Scholar
Wright, JD, Shah, M, Mathew, Let al. Fertility preservation in young women with epithelial ovarian cancer. Cancer, 2009;115(18):4118–4126.Google Scholar
Fruscio, R, Corso, S, Ceppi, L et al. Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol, 2013 January;24(1):138–144.Google Scholar
Fruscio, R, Ceppi, L, Corso, S et al. Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer. Br J Cancer, 2016;115(6):641–648.Google Scholar
Marpeau, O, Schilder, J, Zafrani, Y et al. Prognosis of patients who relapse after fertility-sparing surgery in epithelial ovarian cancer. Ann Surg Oncol, 2008;15:478–483.Google Scholar
Bentivegna, E, Fruscio, R, Roussin, S et al. Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients. Fertil & Steril, 2015;104(5):1319–1324.Google Scholar
Kajiyama, H, Shibata, K, Suzuki, S et al. Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary? Gynecol Oncol, 2008;111:523–526.Google Scholar
Park, JY, Suh, DS, Kim, JH et al. Outcomes of fertility-sparing surgery among young women with FIGO stage I clear cell carcinoma of the ovary. In Gynaecol Obstet, 2016;134(1):49–52.Google Scholar
Petrillo, M, Legge, F, Ferrandina, G et al. Fertility-sparing surgery in ovarian cancer extended beyond the ovaries: a case report and review of the literature. Gynecol Obstet Invest, 2014;77(1):1–5.Google Scholar
Kashima, K, Yahata, T, Fujita, K, Tanaka, K. Outcomes of fertility-sparing surgery for women of reproductive age with FIGO stage IC epithelial ovarian cancer. Int J Gynaecol Obstet, 2013;121(1):53–55.Google Scholar
Kwon, YS, Hahn, HS, Kim, TJ et al. Fertility preservation in patients with early epithelial ovarian cancer. J Gynecol Oncol, 2009;20(1):44–47.Google Scholar
Schlaerth, AC, Chi, DS, Poynor, EA, Barakat, RR, Brown, CL. Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. Int J Gynecol Cancer, 2009;19(7):1199–1204.Google Scholar
Cheng, X, Cheng, B, Wan, X, Lu, W, Xie, X. Outcomes of conservative surgery in early epithelial ovarian carcinoma. Eur J Gynaecol Oncol, 2012;33(1):93–95.Google Scholar
Peccatori, F, Bonazzi, C, Chiari, S et al. Surgical management of malignant ovarian germ-cell tumors: 10 years’ experience of 129 patients. Obstet Gynecol, 1995;86:367–372.Google Scholar
Mitchell, PL, Al-Nasiri, N, A’Hern, R et al. Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases. Cancer, 1999;85:2232–2244.Google Scholar
Brewer, M, Gershenson, DM, Herzog, CE et al. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol, 1999;17:2670–2675.Google Scholar
Tewari, K, Cappuccini, F, Disaia, PJ et al. Malignant germ cell tumors of the ovary. Obstet Gynecol, 2000;95:128–133.Google Scholar
Low, JJ, Perrin, LC, Crandon, AJ et al. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer, 2000;89:391–398.Google Scholar
Zanetta, G, Bonazzi, C, Cantù, M et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol, 2001;19:1015–1020.Google Scholar
Tangir, J, Zelterman, D, Ma, W et al. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol, 2003;101:251–257.Google Scholar
Zanagnolo, V, Sartori, E, Galleri, G et al. Clinical review of 55 cases of malignant ovarian germ cell tumors. Eur J Gynaecol Oncol, 2004;25:315–320.Google Scholar
Boran, N, Tulunay, G, Caliskan, E et al. Pregnancy outcomes and menstrual function after fertility sparing surgery for pure ovarian dysgerminomas. Arch Gynecol Obstet, 2005;271:104–108.Google Scholar
Ayhan, A, Celik, H, Taskiran, C et al. Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer. Eur J Gynaecol Oncol, 2003;24:223–232.Google Scholar
Kang, H, Kim, TJ, Kim, WY et al. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol, 2008;111:106–110.Google Scholar
de La Motte Rouge, T, Pautier, P, Duvillard, P et al. Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor. Ann Oncol, 2008;19:1435–1441.Google Scholar
Satoh, T, Aoki, Y, Kasamatsu, T et al. Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour. Eur J Cancer, 2015 February;51(3):340–351.Google Scholar
Zhang, M, Cheung, MK, Shin, JY et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary-an analysis of 376 women. Gynecol Oncol, 2007;104:396–400.Google Scholar
Gouy, S, Arfi, A, Maulard, A et al. Results from a monocentric long-term analysis of 23 patients with an ovarian Sertoli-Leydig cell tumors. The Oncologist, 2019;24(5):702–709.Google Scholar
Colombo, N1, Peiretti, M, Garbi, A et al.; ESMO Guidelines Working Group.Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012 October;23(Suppl 7):vii20–26.Google Scholar
Schneider, DT, Orbach, D, Cecchetto, G et al. Ovarian Sertoli Leydig cell tumours in children and adolescents: an analysis of the European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT). Eur J Cancer, 2015 March;51(4):543–550.Google Scholar
Zhang, HY, Zhu, JE, Huang, W, Zhu, J. Clinicopathologic features of ovarian Sertoli-Leydig cell tumors. Int J Clin Exp Pathol, 2014 September 15;7(10):6956–6964. eCollection 2014.Google Scholar
Young, RH, Scully, RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol, 1985 August;9(8):543–569. Review.Google Scholar
Schumer, ST, Cannistra, SA. Granulosa cell tumor of the ovary. J Clin Oncol, 2003;21:1180–1189.Google Scholar